Nav: Home

AVN-322 is a safe orally bio-available potent and highly selective antagonist

February 17, 2017

5-hydroxytryptamine subtype 6 receptor (5-HT6R) has been extensively considered as a promising therapeutic target for the treatment of neuropathological disorders. 5-HT6R were hypothesized to be implicated in the processes of learning, memory retention, and cognition. Several selective 5-HT6R ligands are currently undergoing clinical trials for treatment of Alzheimer's disease and schizophrenia, SB-742457 and Lu-AE-58054.

When tested against 70 therapeutic targets including receptors, kinases, ion channels, and transporters, AVN-322 appeared to be highly selective with the only two targets interacting with it, 5-HT6and 5-HT2B receptors.the AVN-322 displayed exclusively high binding affinity to 5-HT6R (Ki=0.39 nM) and potency to block functional cell response to serotonin (Ki=2.85nM, IC50 = 29 nM). Potency of the AVN-322 to block αMe-5-HT response of 5-HT2B expressing cells was 200-fold lower (IC50=6.16μM).

AVN-322 very slowly metabolized (18% degradation by 120 min) in human S9 microsomal fraction and did not inhibit seven major CYP450 cytochromes; only 70%-80% of AVN-0322 was bound to plasma proteins; it had high CACO-2 permeability with no transport asymmetry. AVN-322 showed good oral bioavailability in Wistar rats, 16.4%, dogs, 18%, and monkeys, 47%, and an excellent brain/plasma ratios of 1.6 in mice and 0.4-0.6 in rats.

In vivo testing revealed clear cognition enhancing effect of the AVN=0322. It significantly restored both scopolamine-induced and MK-801-induced cognitive dysfunction and demonstrated antipsychotic potential. In preclinical toxicity studies, both acute and 14-day studies (mice), semi-chronic, 30-days, (monkeys), and chronic, 6-months, (rats and rabbits), AVN-0322 demonstrated reasonably a good safety profile. No undesirable side effects were observed in Phase I human trials with a single dose of 18 mg tested.
-end-
For more information about the article, please visit http://benthamscience.com/journals/current-alzheimer-research/volume/14/issue/3/page/268/

Reference: Ivachtchenko, AV.; et al (2017). AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models. Current Alzheimer Research., DOI: 10.2174/1567205013666161108105005

Bentham Science Publishers

Related Schizophrenia Articles:

First physiological test for schizophrenia and depression
Researchers have found a new way of using proteins in nerve cells to identify people with depression and schizophrenia.
The emergence of a new dopamine hypothesis of schizophrenia
Biological Psychiatry presents a special issue, 'The Dopamine Hypothesis of Schizophrenia,' dedicated to recent advances in understanding the role of dopamine signaling in schizophrenia.
Progress in refining the genetic causes of schizophrenia
An international study led by the University of Exeter Medical School has made advances in understanding the ways in which genetic risk factors alter gene function in schizophrenia.
Exercise can tackle symptoms of schizophrenia
Aerobic exercise can significantly help people coping with the long-term mental health condition schizophrenia, according to a new study from University of Manchester researchers.
In search of neurobiological factors for schizophrenia
It is impossible to predict the onset of schizophrenic psychosis.
A comparison between quetiapine and aripiprazole for treatment of schizophrenia
Schizophrenia is a common cause of incapacity and is ranked as the third most disabling illness subsequent to dementia and quadriplegia.
Four new genetic diseases defined within schizophrenia
Changes in key genes define four previously unknown conditions within schizophrenia, according to a study led by researchers from NYU Langone Medical Center published online April 28 in EBioMedicine, a Lancet journal.
Decrypting a collagen's role in schizophrenia
A small peptide generated from a collagen protein may protect the brain from schizophrenia by promoting the formation of neuronal synapses, according to a paper published in The Journal of Cell Biology.
Two in 5 individuals with schizophrenia have attempted suicide
A new study by the University of Toronto (U of T), released today, found that those with schizophrenia who'd been physically abused during childhood were five times more likely to have attempted suicide.
'Schizophrenia' does not exist, argues expert
The term 'schizophrenia,' with its connotation of hopeless chronic brain disease, should be dropped and replaced with something like 'psychosis spectrum syndrome,' argues a professor of psychiatry in The BMJ today.

Related Schizophrenia Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".